These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33 related articles for article (PubMed ID: 37424558)
1. Evaluation of the BD Phoenix CPO Detect Panel for Detection and Classification of Carbapenemase Producing Lade H; Jeong S; Jeon K; Kim HS; Kim HS; Song W; Kim JS Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508311 [TBL] [Abstract][Full Text] [Related]
2. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients. Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR; Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830 [TBL] [Abstract][Full Text] [Related]
3. First detection of an OXA-48-producing Enterobacter cloacae isolate from currency coins in Algeria. Bendjama E; Loucif L; Chelaghma W; Attal C; Bellakh FZ; Benaldjia R; Kahlat I; Meddour A; Rolain JM J Glob Antimicrob Resist; 2020 Dec; 23():162-166. PubMed ID: 32966913 [TBL] [Abstract][Full Text] [Related]
4. Preferred β-lactone synthesis can explain high rate of false-negative results in the detection of OXA-48-like carbapenemases. Studentova V; Sudova V; Bitar I; Paskova V; Moravec J; Pompach P; Volny M; Novak P; Hrabak J Sci Rep; 2022 Dec; 12(1):22235. PubMed ID: 36564543 [TBL] [Abstract][Full Text] [Related]
5. A Longitudinal Nine-Year Study of the Molecular Epidemiology of Carbapenemase-Producing Duong TTT; Tsai YM; Wen LL; Chiu HC; Chen PK; Thuy TTD; Kuo PY; Hidrosollo JH; Wang S; Zhang YZ; Lin WH; Wang MC; Kao CY Front Microbiol; 2022; 13():703113. PubMed ID: 35359715 [TBL] [Abstract][Full Text] [Related]
6. Molecular epidemiology of environmental and clinical carbapenemase-producing Gram-negative bacilli from hospitals in Guelma, Algeria: Multiple genetic lineages and first report of OXA-48 in Enterobacter cloacae. Bouguenoun W; Bakour S; Bentorki AA; Al Bayssari C; Merad T; Rolain JM J Glob Antimicrob Resist; 2016 Dec; 7():135-140. PubMed ID: 27794265 [TBL] [Abstract][Full Text] [Related]
7. First report of a carbapenemase OXA-48-producing Sevillano L; Herrera C; Valdes Á; de la Hoz Á; Cardeñoso L; Domingo D; Semiglia MA Access Microbiol; 2023; 5(6):. PubMed ID: 37424558 [TBL] [Abstract][Full Text] [Related]
8. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. Yusuf E; Bax HI; Verkaik NJ; van Westreenen M J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806604 [TBL] [Abstract][Full Text] [Related]
9. New β-Lactam-β-Lactamase Inhibitor Combinations. Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185 [TBL] [Abstract][Full Text] [Related]
12. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Doi Y Clin Infect Dis; 2019 Nov; 69(Suppl 7):S565-S575. PubMed ID: 31724043 [TBL] [Abstract][Full Text] [Related]
13. Sequence-based epidemiology of an OXA-48 plasmid during a hospital outbreak. Hidalgo L; de Been M; Rogers MRC; Schürch AC; Scharringa J; van der Zee A; Bonten MJM; Fluit AC Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31591122 [No Abstract] [Full Text] [Related]
14. Current status of ESKAPE microorganisms in Spain: Epidemiology and resistance phenotypes. Sánchez-López J; Cantón R Rev Esp Quimioter; 2019 Sep; 32 Suppl 2(Suppl 2):27-31. PubMed ID: 31475806 [TBL] [Abstract][Full Text] [Related]
17. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276 [TBL] [Abstract][Full Text] [Related]
18. Litrenta J; Oetgen M Trauma Case Rep; 2017 Apr; 8():41-45. PubMed ID: 29644313 [TBL] [Abstract][Full Text] [Related]